Clinical trial
Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma
NCT00484601 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Terminated
Key facts
| NCT number | NCT00484601 |
|---|---|
| Title | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma |
| Official title | Phase II Study of Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Nasopharyngeal Carcinoma |
| Intervention type | Drug |
| Interventions | Ifosfamide, Doxorubicin |
| Enrollment | 9 |
| Start date | Apr 15, 2004 |
| Primary completion | Nov 7, 2007 |
| Completion | Nov 7, 2007 |
| First posted | Jun 11, 2007 |
| Last update posted | Feb 11, 2019 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: